Morning Trading 4 Sep 2019, page-78

OCC trial like that with no comparitor arm can't really give definitive results anyway? The reduction of the need for follow up surgery looks good though but only two years have gone by so maybe the standard treatment is good for two years anyway?

This line illustrates the ambiguity IMO;
'Additionally, the ASES scores reported at 12 months in the trial were comparable or superior to theASES scores at 12 months reported from published studies using similar products.'